| Project/Area Number |
15K09534
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
SATO Shinji 東海大学, 医学部, 教授 (90276238)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SASAKI Noriko 東海大学, 医学部, 助教 (50734406)
|
|---|
| Research Collaborator |
NOGI Shinichi 東海大学, 医学部付属病院, 非常勤医師
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 抗MDA5抗体 / 皮膚筋炎 / 急速進行性間質性肺炎 / 抗体価 / 予後予測 / 再発予測 / 減少率 / 自己抗体 / 抗CADM-140抗体 / 無筋症性皮膚筋炎 / 予後 / サイトカイン |
|---|
| Outline of Final Research Achievements |
Dermatomyositis (DM) is sometimes accompanied by rapidly progressive interstitial lung disease (RP-ILD) especially in patients with clinically amyopathic dermatomyositis (CADM), a clinical subtype of DM. It is known that RP-ILD with DM has a very poor prognosis despite of intensive treatment with high-dose corticosteroid and immunosuppressive agents. Anti-CADM-140/MDA5 (Melanoma Differentiation-Associated Gene 5) antibody (anti-MDA5 antibody) is one of DM-specific autoantibodies and is well known by its close association with RP-ILD. In this study, it was suspected that IL-6 might be involved in the pathogenesis of DM and RP-ILD according to the results of cytokine profile. Our findings also highlight the usefulness of this antibody not only in the prediction of RP-ILD but also in monitoring of the disease activity and prediction of disease outcome both in short-term and long-term follow up.
|
